Brief: FDA Grants Orphan Drug Designation (ODD) To AlloVir’s Posoleucel For The Treatment of Virus-Associated Hemorrhagic Cystitis

Kalaris Therapeutics

04/10/2021 12:57

Oct 4 (Reuters) - Allovir Inc  ALVR.O :
    * FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO ALLOVIR’S
POSOLEUCEL, AN ALLOGENEIC, OFF-THE-SHELF, MULTI-VIRUS SPECIFIC
T-CELL THERAPY, FOR THE TREATMENT OF VIRUS-ASSOCIATED
HEMORRHAGIC CYSTITIS
    * ALLOVIR INC - PHASE 3 REGISTRATIONAL STUDY OF POSOLEUCEL
IN
VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS IS ONGOING

Source text for Eikon:  ID:nBw7wZ9yka 
Further company coverage:  ALVR.O